Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives
Inspira Technologies (NASDAQ: IINN) has engaged a specialized U.S.-based consulting firm to accelerate its strategic initiatives and expansion plans. The consulting firm, which specializes in biotech and medtech companies, will focus on executing high-value strategic transactions and accelerating commercial growth.
This engagement follows several key developments, including major purchase orders, formation of strategic frameworks with government health authorities, and the clinical integration of Inspira's ART100 system in Tier-1 U.S. hospitals. CEO Dagi Ben-Noon emphasized that the partnership aims to facilitate high-impact actions beyond internal execution capabilities, with results expected in the near term.
Inspira Technologies (NASDAQ: IINN) ha incaricato una societ脿 di consulenza specializzata con sede negli Stati Uniti per accelerare le sue iniziative strategiche e i piani di espansione. Questa societ脿, esperta in aziende biotecnologiche e medtech, si concentrer脿 sull'esecuzione di transazioni strategiche di alto valore e sull'accelerazione della crescita commerciale.
Questo incarico segue diversi sviluppi chiave, tra cui importanti ordini di acquisto, la definizione di framework strategici con le autorit脿 sanitarie governative e l'integrazione clinica del sistema ART100 di Inspira negli ospedali Tier-1 degli Stati Uniti. Il CEO Dagi Ben-Noon ha sottolineato che la partnership mira a facilitare azioni ad alto impatto oltre le capacit脿 di esecuzione interne, con risultati attesi a breve termine.
Inspira Technologies (NASDAQ: IINN) ha contratado a una firma de consultor铆a especializada con sede en Estados Unidos para acelerar sus iniciativas estrat茅gicas y planes de expansi贸n. La firma, que se especializa en empresas biotecnol贸gicas y medtech, se enfocar谩 en ejecutar transacciones estrat茅gicas de alto valor y acelerar el crecimiento comercial.
Este compromiso sigue a varios desarrollos clave, incluyendo grandes 贸rdenes de compra, la formaci贸n de marcos estrat茅gicos con autoridades sanitarias gubernamentales y la integraci贸n cl铆nica del sistema ART100 de Inspira en hospitales Tier-1 de EE. UU. El CEO Dagi Ben-Noon enfatiz贸 que la asociaci贸n busca facilitar acciones de alto impacto m谩s all谩 de las capacidades internas de ejecuci贸n, con resultados esperados a corto plazo.
Inspira Technologies (NASDAQ: IINN)電� 氙戈淡鞐� 旮半皹鞚� 霊� 鞝勲 旎劋韺� 須岇偓毳� 瓿犾毄頃橃棳 鞝勲灥鞝� 鞚措媹靺旐嫲敫岇檧 頇曥灔 瓿勴殟鞚� 臧�靻嶍檾頃橁碃 鞛堨姷雼堧嫟. 鞚� 旎劋韺� 須岇偓電� 氚旍澊鞓ろ厤 氚� 氅旊摐韰岉伂 旮办梾鞚� 鞝勲鞙茧 頃橂┌, 瓿犽秬臧�臧�旃� 鞝勲灥 瓯半灅 鞁ろ枆瓿� 靸侅梾鞝� 靹膘灔 臧�靻嶍檾鞐� 歆戩頃� 鞓堨爼鞛呺媹雼�.
鞚措矆 瓿勳暯鞚� 欤检殧 甑Г 欤茧, 鞝曤秬 氤搓贝 雼龟淡瓿检潣 鞝勲灥鞝� 頂勲爤鞛勳泴韥� 順曥劚, 攴鸽Μ瓿� Inspira鞚� ART100 鞁滌姢韰滌澊 氙戈淡 Tier-1 氤戩洂鞐� 鞛勳儊 韱淀暕霅橂姅 霌� 鞐煬 欤检殧 氚滌爠鞐� 霐半ジ 瓴冹瀰雼堧嫟. CEO 雼り赴 氩�-雸堨潃 鞚� 韺岉姼雱堨嫮鞚� 雮措秬 鞁ろ枆 電ル牓鞚� 雱橃柎靹滊姅 瓿犾瀯韺╉姼 臁办箻毳� 齑夓頃橂姅 瓴冹潉 氇╉憸搿� 頃橂┌, 臧�旯岇毚 鞁滌澕 雮挫棎 瓴瓣臣臧� 旮半寑霅滊嫟瓿� 臧曥“頄堨姷雼堧嫟.
Inspira Technologies (NASDAQ : IINN) a engag茅 une soci茅t茅 de conseil sp茅cialis茅e bas茅e aux 脡tats-Unis pour acc茅l茅rer ses initiatives strat茅giques et ses plans d'expansion. Cette soci茅t茅, sp茅cialis茅e dans les entreprises biotechnologiques et medtech, se concentrera sur la r茅alisation de transactions strat茅giques 脿 forte valeur ajout茅e et sur l'acc茅l茅ration de la croissance commerciale.
Cette collaboration fait suite 脿 plusieurs d茅veloppements cl茅s, notamment d'importantes commandes d'achat, la mise en place de cadres strat茅giques avec les autorit茅s sanitaires gouvernementales, et l'int茅gration clinique du syst猫me ART100 d'Inspira dans des h么pitaux Tier-1 aux 脡tats-Unis. Le PDG Dagi Ben-Noon a soulign茅 que ce partenariat vise 脿 faciliter des actions 脿 fort impact au-del脿 des capacit茅s d'ex茅cution internes, avec des r茅sultats attendus 脿 court terme.
Inspira Technologies (NASDAQ: IINN) hat eine spezialisierte US-amerikanische Beratungsfirma beauftragt, um seine strategischen Initiativen und Expansionspl盲ne zu beschleunigen. Die Beratungsfirma, die sich auf Biotech- und Medtech-Unternehmen spezialisiert hat, wird sich auf die Durchf眉hrung wertvoller strategischer Transaktionen und die Beschleunigung des kommerziellen Wachstums konzentrieren.
Dieser Auftrag folgt auf mehrere wichtige Entwicklungen, darunter gro脽e Bestellungen, die Bildung strategischer Rahmenwerke mit staatlichen Gesundheitsbeh枚rden und die klinische Integration von Inspiras ART100-System in Tier-1-Krankenh盲usern in den USA. CEO Dagi Ben-Noon betonte, dass die Partnerschaft darauf abzielt, wirkungsvolle Ma脽nahmen 眉ber die internen Umsetzungskapazit盲ten hinaus zu erm枚glichen, mit Ergebnissen, die kurzfristig erwartet werden.
- Clinical integration of ART100 system achieved in Tier-1 U.S. hospitals
- Secured major purchase orders
- Established strategic frameworks with government health authorities
- None.
Insights
Inspira engages specialized consulting firm to capitalize on recent commercial momentum and accelerate strategic growth initiatives.
Inspira Technologies has made a strategic move by bringing in specialized consulting expertise at what appears to be a critical inflection point in the company's development. This engagement follows what the company describes as significant commercial progress, including major purchase orders, formation of strategic frameworks with government-linked health authorities, and clinical integration of their ART100 system in top-tier U.S. hospitals.
The consulting firm specializes in three key areas that align with Inspira's current needs: structuring high-value strategic transactions, accelerating commercial growth, and transforming enterprise value. This suggests Inspira is preparing for a potential step-change in its business trajectory rather than incremental growth.
CEO Dagi Ben-Noon's statement that the engagement will "fundamentally redefine the scale" of the company indicates management believes they've reached a point where specialized expertise is needed to fully capitalize on their current momentum. The reference to "targeted engagements with high-level stakeholders" points to potential strategic partnerships or commercial arrangements beyond what their internal team can execute independently.
Most notably, the announcement suggests concrete results from these initiatives may materialize in the "very near term" during the second half of 2025, indicating these aren't long-range planning exercises but rather acceleration of already-in-motion initiatives. The focus on "scalable configurations" to expand global footprint suggests the company is positioning for significantly broader market penetration of its life-support and diagnostic technologies.
RA'ANANA, Israel, July 31, 2025 (GLOBE NEWSWIRE) -- Inspira鈩� Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (鈥�Inspira,鈥� 鈥泪苍蝉辫颈谤补 Technologies,鈥� or the 鈥�Company鈥�), a pioneer in innovative life-support and diagnostic technologies, today announced that it has activated a leading consulting firm to accelerate high-impact execution across strategic expansion, partner engagement, and advanced structuring pathways already in motion.
The consulting firm is a specialized group that partners with biotech and medtech companies at critical inflection points. The firm's expertise lies in structuring and leading the execution of high-value strategic transactions, accelerating commercial growth, and transforming enterprise value.
The engagement follows a series of high-impact developments including major purchase orders, the formation of national-level strategic frameworks with government linked health authorities, and clinical integration of Inspira鈥檚 ART100 system in Tier-1 U.S. hospitals. Collectively, these achievements position Inspira to scale its commercial platform and deepen alignment across the broader medtech ecosystem.
鈥淭he current pace and scale of opportunities requires more than internal execution, it demands coordinated, high-impact action,鈥� said Dagi Ben-Noon, CEO of Inspira Technologies. 鈥淲e are already working closely with our consulting firm on several initiatives with significant upside. We expect results from this process to begin surfacing in the very near term, fundamentally redefining the scale of our company.鈥�
The consulting firm is currently facilitating targeted engagements with high-level stakeholders and evaluating scalable configurations to accelerate Inspira鈥檚 global footprint. The objective is to unlock execution pathways that can reshape the Company鈥檚 global market position and catalyze new layers of value creation in the second half of 2025.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company鈥檚 U.S. Food and Drug Administration -cleared INSPIRA鈩� ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA鈩�, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company鈥檚 recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it engaged the consulting firm to accelerate high-impact execution of the Company鈥檚 strategic expansion, partner engagement, and advanced structuring pathways already in motion, the belief that its recent achievements position it to scale its commercial platform and deepen alignment across the broader medtech ecosystem, the belief that the current pace and scale of opportunities require coordinated, high-impact action, the expectation of results from this process to begin surfacing in the very near term, and the objective to unlock execution pathways that can reshape the Company鈥檚 global market position and catalyze new layers of value creation in the second half of 2025. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at .
Company Contact
Inspira Technologies 鈥� Media Relations
Email: [email protected]
Phone: +972-9-9664485
FAQ
What strategic initiatives has Inspira Technologies (IINN) announced in July 2025?
What recent achievements has Inspira Technologies (IINN) reported?
What is the purpose of Inspira Technologies' new consulting partnership?
Where is Inspira Technologies' ART100 system being implemented?
